The Technical Analyst
Acorda Therapeutics Inc [ACOR]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Acorda Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.661
America/New_York / 11 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.821 mill |
| EPS: | -203.57 |
| P/E: | 0 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 1.242 mill |
| Avg Daily Volume: | 0.140 mill |
| RATING 2024-04-11 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.986 - 2.03 ( +/- 289.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-22 | Burns Thomas M. | Buy | 2 400 | Non-Employee Stock Option |
| 2023-06-22 | Burns Thomas M. | Buy | 0 | |
| 2023-06-22 | Varian John | Buy | 1 200 | Non-Employee Stock Option |
| 2023-06-22 | Panem Sandra Phd | Buy | 1 200 | Non-Employee Stock Option |
| 2023-06-22 | Kelley John P | Buy | 1 200 | Non-Employee Stock Option |
| INSIDER POWER |
|---|
| 99.32 |
| Last 96 transactions |
| Buy: 1 532 806 | Sell: 94 790 |
Forecast:
16:00 - $0.613
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.613
Forecast 2: 16:00 - $0.613
Forecast 3: 16:00 - $0.613
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.661 (0.00% ) |
| Volume | 0.322 mill |
| Avg. Vol. | 0.140 mill |
| % of Avg. Vol | 229.96 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACOR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Latest Press Releases
2024-04-15 17:03:00 - Press Release
Acorda Therapeutics Announces Delisting From Nasdaq
Pearl river, n.y.--(business wire)--acorda therapeutics announces delisting from nasdaq.
2024-04-03 17:30:00 - Press Release
Acorda Therapeutics Announces Nasdaq Delisting Notification
Pearl river, n.y.--(business wire)--acorda therapeutics announces nasdaq delisting notification.
2024-04-01 18:35:00 - Press Release
Acorda Therapeutics And Merz Announce Signing Of “stalking Horse” Asset Purchase Agreement
Pearl river, n.y.--(business wire)--acorda therapeutics and merz announce signing of “stalking horse” asset purchase agreement.
2024-01-11 08:01:00 - Press Release
Acorda Therapeutics To Regain Global Commercialization Rights To Fampyra® By January 2025
Pearl river, n.y.--(business wire)--acorda therapeutics to regain global commercialization rights to fampyra® by january 2025.
2023-11-13 16:01:00 - Press Release
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Pearl river, n.y.--(business wire)--acorda therapeutics reports third quarter 2023 financial results.
Latest News
2024-04-01 19:31:00 - Market Watch
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
2023-11-13 17:43:09 - Seeking Alpha
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
2023-05-11 14:26:43 - InvestorPlace
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
Prudent investors are now forced to reassess their portfolios and risk profiles. Indeed, for those invested in penny stocks, the promise of substantial returns is great.
2023-03-06 15:43:00 - Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
2022-11-01 19:49:02 - Seeking Alpha
Acorda Therapeutics, Inc. (ACOR) Q3 2022 Earnings Call Transcript
Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Welcome to Acorda Therapeutics' Third Quarter 2022 Financial and Business Update.
2022-10-31 15:29:05 - Proactive Investors
Acorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting
Acorda Therapeutics Inc (NASDAQ:ACOR) has provided long-term financial guidance and an updated business plan in preparation for the special meeting of its stockholders this week, and updated its net revenue forecast from US$116 million to $121 million in 2023, and as much as $199 million by 2027. The Pearl River, New York-based company said it expects to increase the market for two of its pharmaceuticals – Inbrija for patients with Parkinson's disease, and Ampyra, used to treat adults with multiple sclerosis.
2022-10-25 16:01:00 - Business Wire
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
2022-10-24 14:13:25 - PennyStocks
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
2022-10-18 06:00:00 - PennyStocks
How to Find Penny Stocks to Buy Right Now
Use these tricks for finding penny stocks to buy this week The post How to Find Penny Stocks to Buy Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-08 16:01:00 - Business Wire
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference